NCT03230227

Brief Summary

Effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. Inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery. Infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures. Magnesium is the fourth most plentiful cation in our body. It has antinociceptive effects in animal and human models of pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for not_applicable postoperative-pain

Timeline
Completed

Started Feb 2015

Longer than P75 for not_applicable postoperative-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 14, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 26, 2017

Completed
Last Updated

November 24, 2017

Status Verified

November 1, 2017

Enrollment Period

1.8 years

First QC Date

July 14, 2017

Last Update Submit

November 22, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • postoperative pain

    assessing VAS scale

    2 days

Secondary Outcomes (1)

  • hemodynamics

    24 hours

Study Arms (2)

Bupivacaine magnesium

ACTIVE COMPARATOR

( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours

Drug: Bupivacaine magnesium

bupivacain only

ACTIVE COMPARATOR

bupivacaine 0.125% infusion in the presternum , for 48 hours

Drug: Bupivacaine only

Interventions

bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours

Bupivacaine magnesium

bupivacaine 0.125% infusion in the presternum , for 48 hours

bupivacain only

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • years old
  • American Society of Anesthesiologists physical status II and III
  • Patients scheduled for open heart surgery with sternotomy

You may not qualify if:

  • \- Emergency surgery
  • Clinically significant kidney or liver disease
  • Patients allergic to local anesthetic
  • Patients with prolonged CPB time (\>120 min)
  • Patients required intra-aortic balloon pump

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emad Zarief Kamel Said

Asyut, 71111, Egypt

Location

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: post open heart surgery pain alleviation
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anesthesia and ICU

Study Record Dates

First Submitted

July 14, 2017

First Posted

July 26, 2017

Study Start

February 1, 2015

Primary Completion

December 1, 2016

Study Completion

February 1, 2017

Last Updated

November 24, 2017

Record last verified: 2017-11

Locations